Answers are grounded in this paper and cite their sources.
Short-term cancer risk was not elevated among patients treated with TNFα inhibitor therapy relative to commonly used therapies for immune- mediated chronic inflammatory diseases in this study.
No takes yet. Share an insight, caveat, or question.
Haynes et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: